Mantle Cell Lymphoma
Conditions
Keywords
mantle cell lymphoma
Brief summary
Clinical studies with a distinct emphasis on mantle cell lymphoma play a pivotal role in evaluating the safety and effectiveness of novel treatments for this disease. These trials are instrumental in ascertaining whether new medications surpass conventional therapies, providing substantial evidence to endorse their broad utilization. This particular study stands out as it centers on the firsthand experiences of individuals battling mantle cell lymphoma who are actively engaged in a clinical trial featuring medicinal interventions. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this patient group.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of mantle cell lymphoma * No serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Concurrent participation in another therapeutic clinical trial. * Subject has an uncontrolled infection * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients who remain in a mantle cell lymphoma clinical study to trial completion | 12 months |
| Number of patients who decide to enroll in a mantle cell lymphoma clinical study | 3 months |
Countries
United States
Contacts
Primary ContactMichael B Gill
Outcome results
None listed